Journal article
Humoral and cellular immunity to RSV in infants, children and adults
- Abstract:
-
Background Respiratory syncytial virus (RSV) causes respiratory disease throughout life. Here we report differences in naturally acquired immunity with age and presumed exposure.
Methods A longitudinal, non-interventional, observational study was performed in healthy adults (20 paediatric healthcare workers and 10 non-healthcare workers), children (10 aged 3–6 years) and infants (5 aged 2–4 months and 20 aged 6–12 months). Blood samples were analysed for RSV-neutralising antibody titre, F/Ga/Gb-specific antibody titres, F-specific IgG/IgA memory B-cell frequencies and T-cell production of IFNγ, IL-4, IL-13 and IL-17.
Results Serum G-specific antibody titres were significantly lower in infants and children than adults. However, serum titres of F-specific and RSV-neutralising antibody and IFNγ-producing T-cell frequencies were low or absent in the infants, but comparable between children and adults. Interestingly, F-specific memory IgA B-cells could not be detected in paediatric samples and in samples from non-healthcare workers, but recordable IgA memory B-cells were found in 9/18 paediatric healthcare workers and 2/8 non-healthcare workers at the end of the RSV season. These responses waned 4–6 months later. By contrast, F-specific IgG memory B-cells were detectable in samples from all adults without significant variation across time points. T-cells producing IL-4, IL-13 and IL-17 responses were not detectable in peripheral blood from a subset of volunteers.
ConclusionsRepeated RSV exposure in early life generates immune responses that are inversely related to frequency of severe disease. Induction of F-specific antibody and cellular immune responses through infant vaccination might help to accelerate the development of protective immune responses at an early age.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.vaccine.2018.08.056
Authors
- Publisher:
- Elsevier
- Journal:
- Vaccine More from this journal
- Volume:
- 36
- Issue:
- 41
- Pages:
- 6183-6190
- Publication date:
- 2018-08-31
- Acceptance date:
- 2018-08-21
- DOI:
- EISSN:
-
1873-2518
- ISSN:
-
0264-410X
- Pmid:
-
30177258
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:912259
- UUID:
-
uuid:906348d6-c26a-4ae0-b46f-6165820d1db4
- Local pid:
-
pubs:912259
- Source identifiers:
-
912259
- Deposit date:
-
2018-09-08
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2018
- Notes:
- © 2018 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.vaccine.2018.08.056
If you are the owner of this record, you can report an update to it here: Report update to this record